Streetbeat News

Stock Prices

SNAP

The options market shows a bearish sentiment towards Snap (NYSE:SNAP), with 66% of big-money traders favoring puts over calls. The trading activity suggests a focus on a price range of $8.0 to $11.0. Snap's stock is currently trading at $9.27, with a slight increase of 0.38%.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 4:15 pm

BTCUSD

The cryptocurrency market is showing bearish signs, with Bitcoin's funding rates dropping significantly, while U.S. equities are at all-time highs. This divergence is due to expectations of rate cuts and economic recovery in traditional markets, contrasting with stress in crypto markets.

Portfolio Pulse from Murtuza Merchant

August 19, 2024 | 4:13 pm

GOVX

VRAX

Virax Biolabs Group Limited (NASDAQ:VRAX) shares surged after the WHO declared mpox a global health emergency. The company distributes diagnostic test kits and is developing T-Cell Test technology. GeoVax Labs, Inc. (NASDAQ:GOVX) is also being monitored by investors. Virax shares rose 204.9% amid volatility.

Portfolio Pulse from Erica Kollmann

August 19, 2024 | 4:12 pm

AMD

Advanced Micro Devices, Inc. (NASDAQ:AMD) has announced a $4.9 billion acquisition of ZT Systems, a provider of AI infrastructure. Despite a bullish engulfing pattern indicating potential uptrend, AMD's stock faces resistance at $154.50, a former support level.

Portfolio Pulse from Mark Putrino

August 19, 2024 | 4:09 pm

PLTR

Palantir Technologies Inc (NYSE:PLTR) has seen a 400% increase in its stock price since December 2022, recently surpassing the $30 mark, which could signal further gains. The stock's ability to maintain this level is crucial for future growth.

Portfolio Pulse from Zaheer Anwari

August 19, 2024 | 4:09 pm

FTXH

IBBQ

IDNA

LGHT

MRNA

NVAX

PFE

The FDA is expected to approve updated COVID-19 vaccines from Moderna, Pfizer, and possibly Novovax this week. This approval is in response to a significant summer outbreak in the U.S. Moderna and Pfizer have vaccines ready for distribution, while Novovax's vaccine will be available later this month. Stocks of these companies and related ETFs have shown gains in anticipation of the approval.

Portfolio Pulse from Michael Juliano

August 19, 2024 | 4:08 pm

CNC

Over the past three months, 17 analysts have provided ratings for Centene (NYSE:CNC), with a mix of bullish and bearish sentiments. The average 12-month price target has decreased by 3.11% to $86.47. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Centene, a managed-care organization, has shown revenue growth but faces challenges with net margin and debt management.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 4:01 pm

RGLD

Analysts have mixed ratings for Royal Gold (NASDAQ:RGLD) with recent upgrades in price targets. The average 12-month price target increased by 3.8% to $156.0. Royal Gold shows strong financial performance with high net margins and low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 4:00 pm

ELV

Analysts have provided a range of ratings for Elevance Health (NYSE:ELV) over the past three months, with most being somewhat bullish. The average 12-month price target is $607.47, slightly down from previous estimates. Despite a slight revenue decline, Elevance Health shows strong financial performance with high net margins and ROE. However, it faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 4:00 pm

NKE

Deep-pocketed investors are showing a bullish interest in Nike (NKE) through significant options activity, with a focus on a price range of $40 to $105. Analysts have mixed ratings, with a recent upgrade to 'Buy' and a target price of $93.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 4:00 pm